TOOL: INTERNAL PROVIDER PERFORMANCEREPORT

BALLAD HEALTH

_
a
7
=
~
2
ے
Ξ
~
-0
a
Ü
_
æ
Ε
E
ᅙ
¥
-
, w
Δ.
М
=
₹
-
10
Ω
S
=
·
=
2
<u> </u>
<u></u>
œ
>
ŧ
ā
ٽ
=
<u> </u>
≥.
O

Together 2 Goal® Campaign REPORT BETWEEN: 10/01/2017 AND 08/30/2018	ampaign Measurement	ment				Wellmont Health System	
PROVIDER	PREVALENCE OF TYPE 2 DIABETES	HbA1C CONTROL	BP CONTROL	MEDICAL ATTENTION FOR NEPHROPATHY	LIPID MANAGEMENT	T2G BUNDLE	
OVERALL	24.18	74.73	89.61	92.98	74.91	47.95	
	19.74	68.89	92.22	92.22	87.78	46.67	
	NA	NA	NA	NA	NA	NA	
	29.12	67.17	95.85	90.57	68.79	41.13	
	61.54	75.00	81.25	100.00	50.00	37.50	
	21.72	68.97	84.48	91.38	50.00	31.03	
	16.48	69.42	74.78	80.78	75.73	46.12	
	15.18	72.15	93.67	93.67	55.70	39.24	
	22.15	73.53	82.35	95.59	78.47	57.35	
	22.11	69.76	96.22	93.13	61.51	41.24	
	36.36	37.50	100.00	100.00	75.00	25.00	
	19.98	74.88	92.09	92.09	63.49	46.05	
	4.17	100.00	100.00	100.00	NA	0.00	
	NA	NA	NA	NA	NA	NA	
	NA	NA	NA	NA	NA	NA	
	21.31	96.15	96.15	88.46	88.46	72.08	
	24.92	69.38	91.88	80.63	66.88	38.13	
	18.08	78.89	86.43	95.98	87.94	63.82	
	33.33	NA	NA	100.00	100.00	0.00	
	13.85	57.47	94.25	93.10	51.72	24.14	
	23.05	67.20	88.17	91.94	63.98	40.32	
	25.78	79.22	97.84	95.24	68.83	50.22	
	9.62	80.00	70.00	80.00	50.00	30.00	
	16.03	87.32	90.14	94.37	91.55	73.24	

Note: This report is typically 3 to 4 pages in length to include between 60 and 70 providers based on our current PCP roster.

HbA1C Control BP Control Nephropathy Lipid Management YES
YES
NO
NO
YES
NO
YES
NO
NO
NO
YES
YES
YES
YES
 Female
 NO

 Female
 YES

 Male
 NO

 Female
 NO

 Female
 NO

 Female
 YES

 Female
 YES

 Female
 YES

 Female
 YES

 Male
 YES

 Male
 YES
 Date Of Birth Sex Quarterly Report Listing the Patient-Level Data Behind the Provider's Scores: Patient Name Together 2 Goal® Campaign Measurement Patient Level Report REPORT BETWEEN: 10/01/2017 AND 09/30/2018 Patient MRN

TOOL: NEPHROPATHY IMPROVEMENT

SWEDISHAMERICAN HEALTH SYSTEM

Provider Actions leading to Nephropathy Measure Improvement No Allergic or Prescribe Intolerant? ACEI/ARB Yes Document Intolerance or Allergy Patients in AMGA Prescribe Medications, Type 2 DM cohort Perform Screen, or but not in "Attention Document conditions to nephropathy to show nephropathy numerator" is recognized Order Microalbumin Screening End Document Nephropathy Diagnosis/ Treatment SwedishAmerican Health System developed this care pathway in partnership with Optum,

AMGA's Distinguished Data and Analytics Corporate Collaborator.